Chemring Detection Systems (“CDS”), a division of Chemring Group PLC (“Chemring”), announced today that it has been awarded a Delivery Order under a Full Rate Production contract by the Aberdeen Contracting Command worth $25.2M for the production and delivery of 32 Joint Biological Point Detection Systems (JBPDS) and associated spare parts and services.
These systems will be installed in the Stryker Nuclear Biological Chemical Reconnaissance Vehicle (NBCRV). Deliveries under this agreement will be made from March 2014 through July 2014.
The Joint Biological Point Detection System (JBPDS) provides automatic detection and identification of airborne biological agents at very low levels, triggers local and remote warning systems, and communicates threat information over standard communication systems. The JBPDS program is managed by the Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD). This system is the only US Biological Detection system that went through the Whole System Live Agent Test (WSLAT). The JBPDS is manufactured and tested at the Chemring Detection Systems facility in Charlotte, NC.
“We are pleased to have this opportunity to continue our work with the US Army on the production of this unique Joint Biological Point Detection capability,” said Mark Papworth, CEO. “With over 875 systems currently delivered to US Forces, the JBPDS continues to provide early warning and identification of biological warfare agents, thereby limiting the effects of biological attacks that have the potential for catastrophic effects on the warfighters.”
Chemring is a manufacturing business with facilities in seven countries selling high-technology electronics and energetic products to over 60 countries. The company has a diverse portfolio of products protecting military personnel and platforms against a constantly changing threat. Operating in niche markets with short product development timescales, Chemring has the agility to rapidly react to urgent customer needs. Chemring maintains balanced geographic and market profiles, with a growing presence in non-NATO countries. Strong research and development investment for new products and improvements in technology allows Chemring to expand its addressable markets. For more information, please visit www.chemring.co.uk.